Discovery of the SHP2 allosteric inhibitor 2-((3R,4R)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-(2,3-dichlorophenyl)-3-methylpyrrolo[2,1-f][1,2,4] triazin-4(3H)-one

References

• Grossmann KS, Rosário M, Birchmeier C, Birchmeier W. The tyrosine phosphatase shp2 in development and cancer. Adv Cancer Res. 2010;106:53–89.
   PubMed Web of Science ®Google Scholar
• Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92(4):441–450.
   PubMed Web of Science ®Google Scholar
• Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, et al. Ras nucleotide cycling underlies the SHP2 phosphatase dependence of mutant braf-, nf1- and ras-driven cancers. Nat Cell Biol. 2018;20(9):1064–1073.
   PubMed Web of Science ®Google Scholar
• Rota G, Niogret C, Dang AT, Barros CR, Fonta NP, Alfei F, Morgado L, Zehn D, Birchmeier W, Vivier E, et al. Shp-2 is dispensable for establishing t cell exhaustion and for pd-1 signaling in vivo. Cell Rep. 2018;23(1):39–49.
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, et al. T cell costimulatory receptor cd28 is a primary target for pd-1-mediated inhibition. Science. 2017;355(6332):1428–1433.
   PubMed Web of Science ®Google Scholar
• Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29(4):465–468.
   PubMed Web of Science ®Google Scholar
• Mulero-Navarro S, Sevilla A, Roman AC, Lee DF, D'Souza SL, Pardo S, Riess I, Su J, Cohen N, Schaniel C, et al. Myeloid dysregulation in a human induced pluripotent stem cell model of PTPN11-associated juvenile myelomonocytic leukemia. Cell Rep. 2015;13(3):504–515.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang F, Niu R. Functions of SHP2 in cancer. J Cell Mol Med. 2015;19(9):2075–2083.
   PubMed Web of Science ®Google Scholar
• Zhu G, Xie J, Kong W, Xie J, Li Y, Du L, Zheng Q, Sun L, Guan M, Li H, et al. Phase separation of disease-associated SHP2 mutants underlies MAPK hyperactivation. Cell. 2020;183(2):490–502.e18.
   PubMed Web of Science ®Google Scholar
• Song M, Park JE, Park SG, Lee DH, Choi HK, Park BC, Ryu SE, Kim JH, Cho S. NSC-87877, inhibitor of SHP-1/2 PTPS, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun. 2009;381(4):491–495.
   PubMed Web of Science ®Google Scholar
• Zhang X, He Y, Liu S, Yu Z, Jiang ZX, Yang Z, Dong Y, Nabinger SC, Wu L, Gunawan AM, et al. Salicylic acid based small molecule inhibitor for the oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J Med Chem. 2010;53(6):2482–2493.
   PubMed Web of Science ®Google Scholar
• Shen D, Chen W, Zhu J, Wu G, Shen R, Xi M, Sun H. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers. Eur J Med Chem. 2020;190:112117.
   PubMed Web of Science ®Google Scholar
• Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016;535(7610):148–152.
   PubMed Web of Science ®Google Scholar
• LaMarche MJ, Acker M, Argintaru A, Bauer D, Boisclair J, Chan H, Chen CH-T, Chen Y-N, Chen Z, Deng Z, et al. Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer. J Med Chem. 2020;63(22):13578–13594.
   PubMed Web of Science ®Google Scholar
• Ou SI, Koczywas M, Ulahannan S, Janne P, Pacheco J, Burris H, McCoach C, Wang J, Gordon M, Haura E, et al. A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial. J Thoracic Oncol. 2020;15(2):S15–S16.
   PubMed Web of Science ®Google Scholar
• Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108.
   PubMed Web of Science ®Google Scholar
• Fodor M, Price E, Wang P, Lu H, Argintaru A, Chen Z, Glick M, Hao HX, Kato M, Koenig R, et al. Dual allosteric inhibition of shp2 phosphatase. ACS Chem Biol. 2018;13(3):647–656.
   PubMed Web of Science ®Google Scholar
• Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):271–281.
   PubMedGoogle Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40(Pt 4):658–674.
   PubMed Web of Science ®Google Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486–501.
   PubMed Web of Science ®Google Scholar
• Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. Phenix: a comprehensive python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 2):213–221.
   PubMed Web of Science ®Google Scholar
• Gee KR, Sun W-C, Bhalgat MK, Upson RH, Klaubert DH, Latham KA, Haugland RP. Fluorogenic substrates based on fluorinated umbelliferones for continuous assays of phosphatases and β-galactosidases. Anal Biochem. 1999;273(1):41–48.
   PubMed Web of Science ®Google Scholar
• Welte S, Baringhaus K-H, Schmider W, Müller G, Petry S, Tennagels N. 6,8-difluoro-4-methylumbiliferyl phosphate: a fluorogenic substrate for protein tyrosine phosphatases. Anal Biochem. 2005;338(1):32–38.
   PubMed Web of Science ®Google Scholar